TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33749041
Drug: DBB (Deproteinized
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBB (Deproteinized Bovine Bone) with SA-H (Sandblasting + acid attack + immersion in 0.9% sodium chloride isotonic solution)
Study: 33749041
Drug: DBB/BM (Deproteinized
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBB/BM (Deproteinized bovine bone associated with fresh autologous bone marrow) with SA-H (Sandblasting + acid attack + immersion in 0.9% sodium chloride isotonic solution)
Study: 35476631
Drug: 150 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg/kg ivermectin
Study: 35450573
Drug: Metoprolol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 150 mg
Study: 33409591
Drug: Sequential romosozumab-to-alendronate
Normalized name: romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential romosozumab-to-alendronate treatment
Study: 32672427
Drug: Renal-replacement therapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal-replacement therapy initiation timing
Study: 33188966
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for lateral ankle sprain
Study: 33616875
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (BI)
Study: 35901105
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control group (regular physical activity)
Study: 34275593
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 to 100 mg/day, flexibly titrated by week 6)
Study: 33891569
Drug: Neem capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem capsules (50 mg of neem-leaf extract, twice a day for 28 days)
Study: 33891569
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (twice a day for 28 days)
Study: 33891569
Drug: Neem capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem capsules
Study: 33891569
Drug: Neem capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem capsules and Placebo
Study: 35010916
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg twice daily)
Study: 32000093
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), 12 sessions
Study: 35837991
Drug: empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 10 mg
Study: 35000470
Drug: Stellarex low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stellarex low-dose paclitaxel drug-coated balloon (DCB)
Study: 32369162
Drug: Smoked cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis administration (50.6 mg THC)
Study: 32369162
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis administration (50.6 mg THC)
Study: 32369162
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis administration (50.6 mg THC)
Study: 33736940
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (50‐54 Gy to the mediastinum using intensity‐modulated radiation therapy or proton beam therapy)
Study: 33047127
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg nicotine/mL cherry
Study: 33047127
Drug: 18 mg/mL
Normalized name: menthol 18 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/mL cherry
Study: 33047127
Drug: 6 mg/mL
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/mL chocolate
Study: 33047127
Drug: 18 mg/mL
Normalized name: menthol 18 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/mL chocolate
Study: 33210434
Drug: 10 mg/mL
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL triamcinolone acetonide (TA)
Study: 33210434
Drug: 5 mg/mL
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/mL triamcinolone acetonide (TA)
Study: 33210434
Drug: 2.5 mg/mL
Normalized name: iodine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/mL triamcinolone acetonide (TA)
Study: 35791616
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea leaf extract (GTE) tablet
Study: 35931636
Drug: SARS-CoV-2 vaccine
Normalized name: SARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccine group
Study: 35390511
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg per day for 14 days
Study: 32820003
Drug: Spiriva Respimat
Normalized name: Spiriva Respimat
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva Respimat (2.5 μg twice a day) in combination with ICS/LABA
Study: 32820003
Drug: Spiriva HandiHaler
Normalized name: Spiriva HandiHaler
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva HandiHaler (18 μg once a day) in combination with ICS/LABA
Study: 33913348
Drug: Food and
Normalized name: ThickenUp Clear Instant Food and Beverage Thickener Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food and Nutrition Education Program with Sensory and Cognitive Exercises (PESC), consisting of four weekly workshops.
Study: 33913348
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no workshops), evaluated twice with a one-month interval.
Study: 34994286
Drug: N-acetylcysteine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine plus low dose contraceptive
Study: 34994286
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose contraceptive alone
Study: 33201202
Drug: Care bundle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care bundle including early intravenous nitrate boluses, management of precipitating factors, and moderate dose of intravenous diuretics (median 27.0 mg of intravenous nitrates in the first 4 hours).
Study: 36111429
Drug: Erenumab (ERE)
Normalized name: erenumab
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab (ERE) 140 mg
Study: 33249580
Drug: Galcanezumab (GMB)
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab (GMB) 240 mg
Study: 32791965
Drug: Pre-anesthesia best
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-anesthesia best possible medication history (PA-BPMH) performed by a clinical pharmacist
Study: 36286834
Drug: Selective VDRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective VDRA (zemplar 1 mcg/day)
Study: 36286834
Drug: Non-selective VDRA
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective VDRA (alfacalcidol 0.25 mcg/day)
Study: 32569068
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin powder (1000 mg)
Study: 36410628
Drug: Topical lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine-prilocaine
Study: 34420949
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 2.3 g of omega-3 fatty acids (n-3 FAs)
Study: 35899748
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2000 IU/day vitamin D and 1g/day omega-3 fatty acids for 5 years
Study: 35897060
Drug: Trifluridine/tipiracil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil plus panitumumab (6 mg/kg body weight, intravenously on day 1 and 15, q28 days)
Study: 35897060
Drug: Trifluridine/tipiracil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil plus bevacizumab (5 mg/kg body weight, intravenously on day 1 and 15, q28 days)
Study: 33423966
Drug: Stereotactic radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiation therapy
Study: 32992898
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus acidophilus, L. casei, L. helveticus, Bifidobacterium bifidum) for 60 days (n = 8)
Study: 32978696
Drug: Melatonin (MLT)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MLT) 40 mg/kg
Study: 32978696
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 2 mg/kg
Study: 35606865
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic bowel preparation (OABP) with neomycin 1 g and metronidazole 0.9 g the day before surgery
Study: 35606865
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special intestinal preparation (control group)
Study: 33068445
Drug: 3-point intramuscular
Normalized name: menthol 41.3 MG/ML [ActivOn Joint & Muscle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-point intramuscular injection technique (8-12 units of incobotulinumtoxinA)
Study: 33068445
Drug: 6-point intradermal
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-point intradermal injection technique (8-12 units of incobotulinumtoxinA)
Study: 33068445
Drug: 3-point intramuscular
Normalized name: menthol 41.3 MG/ML [ActivOn Joint & Muscle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-point intramuscular injection technique
Study: 33068445
Drug: 6-point intradermal
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-point intradermal injection technique
Study: 33236464
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus add-on linagliptin
Study: 33236464
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of metformin
Study: 35767683
Drug: Intradialytic range-of-motion
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic range-of-motion exercises (30-minute weekly sessions)
Study: 32870583
Drug: Intranasal chemical
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal chemical trigeminal stimulation with carbon dioxide
Study: 35846226
Drug: Lebrikizumab 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 125 mg
Study: 38700646
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg
Study: 33160359
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg) plus docetaxel (75 mg/m2)
Study: 33160359
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg) plus docetaxel
Study: 33386826
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy (twice a day)
Study: 34181580
Drug: Rg1 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rg1 (5 mg) supplementation 1 hour before squat exercise
Study: 34181580
Drug: Rg1 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rg1 (5 mg) supplementation
Study: 35550371
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid prescription (ten 5-mg oxycodone tablets provided preoperatively)
Study: 35550371
Drug: Restricted opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted opioid prescription (provided only during patient request postoperatively)
Study: 32652462
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS reminder
Study: 35382842
Drug: TAK228 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK228 plus weekly paclitaxel
Study: 35382842
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel alone (standard treatment)
Study: 32560503
Drug: Ketogenic Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic Diet Therapy (KDT) including classic ketogenic diet (cKD), modified Atkins diet (MAD), medium chain triglyceride ketogenic diet (MCTKD), low glycemic index treatment (LGIT)
Study: 32518064
Drug: SU (glimepiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU (glimepiride 1 mg) + GIP (1.5 pmol/kg/min)
Study: 32518064
Drug: SU (glimepiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU (glimepiride 1 mg) + GLP-1 (0.5 pmol/kg/min)
Study: 32518064
Drug: SU (glimepiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU (glimepiride 1 mg) + placebo
Study: 35955129
Drug: Eccentric hamstring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric hamstring training (6 weeks, twice weekly) in post-PHV group
Study: 35955129
Drug: Eccentric hamstring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric hamstring training (6 weeks, twice weekly) in pre-PHV group
Study: 33049804
Drug: SPN-812 (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 (1,800 mg)
Study: 35460601
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg once daily)
Study: 34000112
Drug: Pharmacist Comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist Comprehensive Medication Management Services (PCS)
Study: 34000112
Drug: Pharmacist Comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist Comprehensive Medication Management Services (PCS) and Modified or No CMM Services (NCS)
Study: 32925435
Drug: IVRA with
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRA with 300 mg lidocaine
Study: 32925435
Drug: Axillary block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axillary block with 280 mg mepivacaine
Study: 33675672
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy along with a Stroke rehabilitation program
Study: 33675672
Drug: Stroke rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke rehabilitation program without mirror therapy
Study: 35286136
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus standard chemotherapy
Study: 35696601
Drug: Local Vibration
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Vibration Therapy (VT) for 10 minutes at 45 Hz, starting 1 hour post-exercise, applied twice daily for 48 hours
Study: 35696601
Drug: Local Vibration
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Vibration Therapy (VT)
Study: 33510503
Drug: Substandard medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Substandard medicines found in health facilities
Study: 33510503
Drug: Labeling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeling and storage conditions of medicines
Study: 34621011
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg/day plus androgen deprivation therapy (ADT)
Study: 34621011
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg/day plus ADT
Study: 33556352
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) sessions
Study: 33556352
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (yoga, PT, education)
Study: 34386129
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy defibrillator (CRT-D)
Study: 33538520
Drug: Clinicopathological model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicopathological model (4 risk factors: obstruction or perforation, lymphovascular invasion, tumor budding, no chemotherapy)
Study: 32139135
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg kg‐1
Study: 32139135
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg kg‐1 (maximum 5 mg)
Study: 33593781
Drug: Continuous landiolol
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous landiolol infusion to reduce heart rate between 80 and 94 bpm
Study: 32564920
Drug: Intravitreal sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal sirolimus 44 μg
Study: 32564920
Drug: Intravitreal sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal sirolimus 440 μg
Study: 32564920
Drug: Intravitreal sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal sirolimus 880 μg
Study: 33305993
Drug: Oral oncolytic
Normalized name: Telomerase Specific Replication-competent Oncolytic Adenovirus
DrugBank: Suratadenoturev (DB18672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oncolytic agents (OAs)
Study: 34487441
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin plus GLP-1 RA
Study: 34487441
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin plus SGLT2 inhibitor
Study: 34487441
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin intensification
Study: 35568679
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in COU-AA-301-AAP
Study: 35568679
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in COU-AA-302-AAP
Study: 35568679
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in COU-AA-302-P
Study: 35568679
Drug: Metformin pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin pooled analysis
Study: 35951432
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (one piece for 15 minutes, 3 times daily)
Study: 33443117
Drug: Gaboxadol 15
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 15 mg evening dose (qd)
Study: 33443117
Drug: Gaboxadol 10
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 10 mg morning dose and 15 mg evening dose (bid)
Study: 33443117
Drug: Placebo morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo morning dose and evening dose
Study: 32870155
Drug: Both propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both propofol MCT and LCT preparations
Study: 39106541
Drug: Nabiximols oromucosal
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols oromucosal spray
Study: 33430665
Drug: Amlodipine (Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (Calcium Channel Blocker)
Study: 37295665
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg daily for 12 weeks
Study: 33597580
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg doses administered via chewing gum, four doses during night-time)
Study: 33822798
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera capsule
Study: 35570039
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 144)
Study: 33761901
Drug: US-guided bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided bilateral posterior TAPB with RSB (40 mL 0.33% ropivacaine + 20 mL 0.33% ropivacaine)
Study: 32604406
Drug: Pimodivir 600
Normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimodivir 600 mg plus oseltamivir 75 mg twice daily for 7 days
Study: 32604406
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oseltamivir 75 mg twice daily for 7 days
Study: 32678716
Drug: Neratinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (240 mg once daily) plus capecitabine (750 mg/m2 twice daily for 14 days of a 21-day cycle)
Study: 32678716
Drug: Lapatinib (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,250 mg once daily) plus capecitabine (1,000 mg/m2 twice daily for 14 days of a 21-day cycle)
Study: 33272281
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–piperaquine (DP)
Study: 34275096
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (20 mg daily for 5 days, followed by 10 mg daily for 5 days)
Study: 33818302
Drug: CBT‐based Complicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐based Complicated Grief Treatment (CGT)
Study: 36332541
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (IM)
Study: 36332541
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (IN)
Study: 32560516
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day CLA
Study: 35380374
Drug: ON-SXB 6
Normalized name: 2-Mercapto-6-propylpyrimid-4-one
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ON-SXB 6 g